Primary Venture Partners的动态

For Primary’s NYC Seed Report, Bryce Johnson explores how AI-powered healthcare workforce management platforms like M7 Health and Arya Health are addressing the industry's staffing inefficiencies by offering real-time scheduling, operational insights, and benefits management solutions. https://lnkd.in/gTd4X3qS

Bryce Johnson has been named one of TechCrunch’s New York’s top VCs under 30. This recognition highlights the rising stars in venture capital who are already making their mark and shaping the future of the industry in NYC. Congrats, Bryce! https://lnkd.in/gAASmn2E

Initially, PBMs aimed to make pharmacy claims processing less of a hassle. Gone were the days of shoeboxes full of receipts. Instead, they brought in electronic systems to streamline the process. PBMs leveraged bank identification numbers to modernize prescription workflows. The goal? To manage the vast number of prescriptions efficiently. While it began as a way to simplify prescription management, the role of PBMs has evolved into a complex system of price negotiation and cost reconciliation. Curious about how this all fits together? Dive into the full story featuring this serial healthcare entrepreneur. Link in the comments.

In Q3 2024, the NYC seed funding landscape saw a strategic pivot. While total funding dropped 13%, the average round size rose by 11%, signaling a high-conviction, low-volume approach from investors. Healthtech, AI, and FinTech deals led the way, with notable growth in transactions within the $6M-$10M range. Explore these evolving trends with industry experts Tobias Citron, Zach Fredericks, Bryce Johnson, Gaby Lorenzi, Gabriella Monico, and Rachel Pavey in Primary's Q3 NYC Seed Report. https://lnkd.in/gTd4X3qS

Who really calls the shots at a PBM? It’s not the execs or even the section heads running the rebate, network, or underwriting teams. At the end of the day, it’s the shareholders. Publicly traded PBMs have one key priority: maximizing profits every quarter—and that’s where things get messy. This healthcare founder, with a company valued at over $1 billion, insists that a PBM’s business model is built to keep investors happy, not to serve patients. Shareholder pressure keeps growing, pushing PBMs to focus on profits over people. In this chat hosted by Sam Toole, Partner at Primary, our confidential source dives into how PBMs are driving up drug prices. Link to the full conversation in the comments.